Skip to main content

Table 5 Post chemotherapy treatment (N = 89) Table legend text

From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

Post chemotherapy N %
Irinotecan-based regimen 54 60.7
Oxaliplatin-based regimen 16 18.0
Chemotherapy with bevacizumab 37 41.6
Chemotherapy with cetuximab 32 36.0
Chemotherapy with panitumumab 21 23.6